Instil Bio, Inc.
For the period ended May 28, 2025. Filed Apr 14, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 28, 2025 · Filed Apr 14, 2025
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
DEF 14A 1 instilbioproxy2025.htm DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrantx
Filed by a Party other than the Registranto
Check the appropriate box:
| o | Preliminary Proxy Statement |
|---|---|
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x | Definitive Proxy Statement |
| o | Definitive Additional Materials |
| o | Soliciting Material Pursuant to § 240.14a-12 |
Instil Bio, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
| x | No fee required. |
|---|---|
| o | Fee paid previously with preliminary materials |
| o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
3963 Maple Avenue, Suite 350
Dallas, Texas 75219
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held On May 28, 2025
Dear Stockholder:
You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of INSTIL BIO, INC., a Delaware corporation (the “Company”). The meeting will be held on Wednesday, May 28, 2025 at 11:00 a.m., Central Time at our corporate headquarters located at 3963 Maple Avenue, Suite 350, Dallas, Texas 75219 for the following purposes:
To elect one director nominee, Bronson Crouch, as a Class I director to hold office until the 2028 Annual Meeting of Stockholders.
To ratify the selection by the Audit Committee of the board of directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2025.
To conduct any other business properly brought before the meeting.
These items of business are more fully described in the Proxy Statement accompanying this Notice.
The record date for the Annual Meeting is April 2, 2025 (the “Record Date”). Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to BeHeld on May 28, 2025 at 11:00 a.m., Central Time.The proxy statement and annual report to stockholdersare available at http://www.proxyvote.com.
By order of the board of directors,
/s/ Sandeep Laumas, M.D.
Sandeep Laumas, M.D.
Chief Financial Officer and Chief Business Officer
Dallas, TX
April 14, 2025
You are cordially invited to attend the Annual Meeting. Whether or not you expect to attend the meeting, please vote over the telephone or the internet as instructed in these materials, or, if you receive a paper proxy card by mail, by completing and returning the proxy mailed to you as promptly as possible in order to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.
Table of Contents
| Page | |
|---|---|
| QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING | 1 |
| PROPOSAL 1 ELECTION OF DIRECTORS | 7 |
| INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE | 10 |
| Independence of the board of directors | 10 |
| Board Leadership Structure | 10 |
| Role of the Board in Risk Oversight | 11 |
| Meetings of the board of directors | 11 |
| Information Regarding Committees of the board of directors | 11 |
| Audit Committee | 12 |
| Compensation Committee | 13 |
| Nominating and Corporate Governance Committee | 14 |
| Stockholder Communications with the board of directors | 15 |
| Code of Ethics | 16 |
| Hedging Policy | 16 |
| PROPOSAL 2 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 17 |
| Independent Registered Public Accounting Firm Fees and Services | 17 |
| Pre-Approval Policies and Procedures | 17 |
| EXECUTIVE OFFICERS | 19 |
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 20 |
| DELINQUENT SECTION 16(A) REPORTS | 22 |
| EXECUTIVE COMPENSATION | 23 |
| Summary Compensation Table | 23 |
| Outstanding Equity Awards as of December 31, 2024 | 26 |
| Clawback Policy | 29 |
| DIRECTOR COMPENSATION | 30 |
| SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS | 32 |
| TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION | 33 |
| Related-Person Transactions Policy and Procedures | 33 |
| Certain Related-Person Transactions | 33 |
| Indemnification | 34 |
| HOUSEHOLDING OF PROXY MATERIALS | 35 |
| OTHER MATTERS | 36 |
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.